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Third-generation oral contraceptive and deep venous
thrombosis: From epidemiologic controversy to new insight
in coagulation
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Frits R. Rosendaal, MDa c
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Four epidemiologic studies showed a twofold increase in nsk of deep venous thrombosis with the use of
oral contraceptives contammg third-generation progestins, relative to second-generation products These
findmgs have been strongly debated ever smce, and new studies have been added In the current article
we examme whether the findmgs can be explained by potential biases or other shortcommgs of the
epidemiologic studies We conclude that complete certainty cannot exist but that the most rational
conclusion from the epidemiologic findmgs and their discussion is that an increased risk of deep venous
thrombosis with third generation contraceptives is hkely, especially in first time and young users The
controversy has recently led to new msights in coagulation Women who use third-generation
contraceptives acquire a resistance to the blood's own anticoagulation System, similar to the activated
protem C resistance that is seen in persons who carry the factor V Leiden mutation but different from that
m women usmg second-generation contraceptives (Am J Obstet Gynecol 1997,177 887-91 )
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In December 1995 andjanuary 1996, four epidemio-
logic studies were published, showing that the nsk of
deep venous thrombosis with "third generation contra-
ceptives" is two ümes higher than with second generation
pills T 4 The major third-generation contraceptives con-
tam 30 μg ethinyl estradiol, in combmaüon with deso-
gestrel or gestodene The latter formulations are deriva
tives of levonorgestrel, the main second-generation
progestm Another derivative, norgesümate, is difficult to
classify because it is partially metabohzed to levonorg-
estrel and partially to other mtermediates Very low-dose
pills contammg a third generation progestm m combma
tion with 20 μg ethinyl estradiol were also introduced In
the United States third-generation contraceptives con-
tain desogestrel or norgesümate, in Europe they also
contam gestodene
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The studies
The original findmg of an elevated venous thrombosis
risk with third generation contraceptives was in a world-
wide case control study on the side effects of oral contra
cepüves by the World Health Orgamzaüon (WHO)5, the
evidence on third- versus second-generation contracep
üves was found in the analysis of the European subset of
the study and was based on 769 cases, 1979 hospital
controls, and 246 Community controls The relative nsk
for venous thrombosis among useis of third generation
contraceptives m companson with second-generation
users was 2 6, m companson with nonusers the relative
risk was 9 l These unexpected findings were confirmed
by a cohort analysis and a nested case-control study in the
United Kingdom General Practice Research Data-base
(UK-GPRD), based on 80 cases of nonfatal venous throm-
bosis among 238,130 otherwise healthy women The
relative risks of the third-generation products relative to
those of second generation ones were l 8 and 1 9 m the
cohort analysis and 2 2 and 2 l in the nested case-control
analysis A second confirmaüon came from the reanalysis
of a Dutch case-control study, ongmally set up to study
hereditary risk factors m venous thrombosis 126 women
with venous thrombosis and 159 controls yielded a
relative risk of 2 5 for the desogestrel-contaimng third-
generation contraceptive relative to the second-genera
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tion one and an overall relative risk of 8.7 relative to
nonusers. A third confirmation came from an industry-
sponsored case-control study across Europe, the Transna-
tional study, with a protocol that was very close to that of
the WHO study, in which 471 cases and 1772 controls
yielded a relative risk of 1.5 for third-generation products
in comparison with a mix of other products.
The risks
The baseline incidence of deep venous thrombosis
among young women who do not use oral contraception
is between 0.5 and l per 10,000 per year1"3; this is
increased threefold to fourfold by second-generation
contraceptives5 and, according to the four studies, an-
other two times by third-generation contraception. In
comparison with that of nonusers, the overall risk of
third-generation contraceptive users might be increased
eightfold. The case fatality rate of venous thrombosis is
between 1% and 2% in young persons.6 The absolute
risks are small. However, the first question is whether the
observation that third-generation contraceptives increase
the risk of venous thrombosis more than second-gener-
ation products is valid.
The biases
The publications were followed by a large correspon-
dence and a series of other publications pointing at
possible biases in the four studies (see our acknowledg-
ment at the end of the article). The central argument was
that the size of the relative risk of third- versus second-
generation contraceptives, a twofold increase of venous
thrombosis, is in a ränge that makes it susceptible to bias.
Similarly, it was argued that the remarkable consistency
of four studies across Europe, with different protocols
and different funding arrangements, all finding a ele-
vated risk of third-generation contraceptives, has little
meaning in itself: They all might have been biased in the
same way. When such arguments are used, however, it is
necessary to specify the biases—to examine whether they
can in effect be operating and what evidence we need to
answer them.
"Starter" and "healthy user" bias. The first objection
is that venous thrombosis associated with third-genera-
tion contraception would occur mainly in young first-
time users who have started contraception with the
newer puls. Among these new users are women who are
susceptible to the thrombogenic effects of contraceptives
because they have never been "challenged." In contrast,
second-generation pill users are represented mainly by
women who have already used oral contraceptives for a
long time and who have never had thrombosis; therefore
they have stayed with their trusted brand. They are the
"healthy users."
If this theory is true, the difference between third- and
second-generation products should disappear when we
look separately at first venous thrombosis in new users.
This was possible in three studies; the effect did not
disappear. In the Transnational study a separate analysis
for first-time users yielded a relative risk of third- versus
second-generation pills of 2.7; for continued use the
relative risk was l A.4 In the UK-GPRD the relative risk of
thrombosis for third-generation versus second-genera-
tion products during the first 6 months of use was 9.2 for
desogestrel and 5.6 for gestodene; after that time it
became 1.8.2 In the WHO study the overall relative risk in
first-time users of third- versus second-generation pills
was 5.4, which lowered to 2.4 thereafter.1 Similarly ele-
vated risks in new users were found in two new studies: a
case-control study from Denmark and a pharmacoepide-
miologic linkage study in The Netherlands.7'8
The WHO investigators provided an additional cross
tabulation for type of oral contraceptive, for the first year
of use, and for new users separately.9 Whereas the risk
was always higher in the first year of use among new
users, the relative distance between third- and second-
generation products remained about twofold. (Relative
to nonusers the risk among new users during the first
year of use was twentyfold for third-generation contra-
ceptives, which lowered to tenfold afterward. For second-
generation contraceptives the relative risk was ninefold
for first year of use among new users, which lowered to
twofold to threefold afterward.) This shows that there
might indeed be a "starter" effect but also that this effect
is stronger for third-generation contraceptives. Because
the analysis is now separate for new and recent users,
"likes" are compared with "likes," and there is no more
room for this bias.
The "recency of introduction" bias. A reanalysis of a
subset of the Transnational study showed that the relative
risks of deep venous thrombosis are higher for recently
introduced contraceptives.10 The authors called this phe-
nomenon the "attrition of susceptibles." It is the same äs
the "starter" and "healthy user" bias, and the problem
was solved in the above-described analyses. In addition,
this finding in the Transnational study only held for one
age category (containing only about half of the cases in
the study); close examination of the published data in
subsequent correspondence has shown that the trend
with recency of introduction did not exist among the
youngest users (see our acknowledgment at the end of
the article).
"Prescribing" bias. The second objection is that third-
generation products were preferentially prescribed to
women at high risk for venous thrombosis. When exam-
ining this argument, we should specify what could make
a physician predict that a young women who has never
had a venous thrombosis previously has a higher risk for
venous thrombosis.
Textbooks on venous thrombosis offer very few clinical
risk factors that predict the occurrence of a first venous
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thrombosis m healthy young persons (see our acknowledg-
ment at the end of the article) The Status of superficial
vancose vems äs a nsk factor for deep venous thrombosis is
debated11, they lead mainly to superficial thrombosis Su-
perficial vancose vems may result from an earlier venous
thrombosis, but women with an earlier thrombosis were
excluded from all studies Obesity is a weak nsk factor,
except for gross obesity (which is mfrequent in young
first-üme users) Contrary to widespread belief, smokmg is
not a nsk factor for venous thrombosis (in contrast to
arterial thrombosis) A clear nsk factor for venous throm-
bosis is family history, in particular, when coupled with the
factor V Leiden mutaüon 3 Knowledge about this geneüc
risk is of a much more recent date than the collection of the
paticnts for the studies All risk factors that are likely to have
been screened for at first prescnption of the oral contra-
ceptive, such äs smokmg, hypertension, alcohol use, serum
cholesterol, familial cardiovascular disease, diabetes, and
others, are risk factors for arterial, not venous, thrombosis
A Dutch pharmacoepidermologic linkage study
showed that women who use other cardiovascular medi-
cation, for example, oral anticoagulation, use third-
generation contraceptives more often 8 Third-generation
contraceptives would have been prescribed to women
who had been barred from second-generation pills m the
past, because the newer pills were perceived äs safer This
putative extension of prescnption to women with contra-
mdications concerns nsk factors for arterial thrombosis
and not for venous thrombosis In the case of oral
anticoagulation this medication will have been started
because of an episode of venous thrombosis or another
medical indication This could never have biased aiiy of
the four studies, because all studies were hmited to first
thrombosis and women who were on a regimen of
anticoagulation would have been excluded
In the WHO study, äs well äs the Transnational study,
which adhered to the same protocol, and in the UK-GPRD
study all women with major disease leadmg to prolonged
immobilization were excluded Whereas there might have
been women in these studies whose prescnption of third-
generation contraceptives was one of the recent extensions,
at maximum, this might have included some with mild
hypertension, hypercholesterolemia, or mild diabetes,
which m the early uncomphcated stages are not nsk factors
for venous thrombosis Risk factors that were not excluded,
such äs venous thrombosis after trauma or elective surgery
in a young women, are unpredictable at the time of
prescnbmg oral contraceptives
There are also "utihzation studies" m which doctors
have been asked what pill they would consider m differ-
ent risk circumstances (see our acknowledgment at the
end oi the article) Doctors have answered that m known
nsk situations they would prescribe the pill that is
perceived to be safest When a companson was made
with their actual practice, they adhered less to their ideal
behavior,12 which is a common findmg m studies about
the quahty of actual medical care The studies showed
that doctors are very often "blanket prescnbers "
Although the "selective prescnption" argument seems
tenuous, because it is unhkely that a routmely prescnb-
mg physician can predict whether a first venous throm-
bosis will develop m a healthy young woman, the mflu-
ence of several risk factors was assessed in the four
studies Analyses were published with and without strati-
fication for age and for all putative nsk factors, alone or
in several combmations—obesity, family history of ve-
nous thrombosis, factor V Leiden mutaüon, superficial
vancose vems, previous pregnancies, hypertension dur-
ing pregnancy, smokmg, and alcohol use The relative
risk of third- versus second-generation products always
remamed mcreased ' 4 The four studies overlap in their
capacity to meet the criücisms All known biases and
confounders, except family history of thrombosis, have
been addressed by the WHO study Family history was
addressed in the Leiden study
The 20 μ§ and the norgestimate objection. In several
studies the highest risk was found for the most recently
mtroduced third-generation contraceptive contammg
only 20 μg ethinyl estradiol l 10 l^ Although the numbers
are small, this has been brought äs evidence for selective
prescnbmg, because it is illogical to find the highest risk
with the lowest-dose pills A study based on the MediPlus
database m Britam, on 83 cases and a total of 202,517
woman years, found an oveiall relative risk of third-
generation versus second-generation contraceptives of
l 7 ls On subgroup analysis in a nested case-control study
with close age matchmg, only the relative risk of the 20
μg product remamed elevated It was argued that the age
pattern for prescnption of this contraceptive was differ-
ent The study was criticized in subsequent correspon-
dence for includmg unvenfied cases and because the
original studies retamed their original relative nsks also
after reanalysis with closer age matchmg (see our ac-
knowledgment at the end of the article) A possible
explanation of the unexpected findmg of the highest risk
with the 20 μg product is a combmation of a "starter
effect" with a third-generation effect The very high
relative risks associated with this contraceptive corre-
spond with the risk in the first year of use among new and
recent users of third-generation contraceptives m the
WHO study °
A similar objection has been made about the norges-
timate-contaming contraceptive that is difficult to classify
äs second or third generation The extent to which it is
metabohzed to the second-generation levonorgestrel is
leported differently (see our acknowledgment at the end
of the article) It has metabolic effects (on high-density
hpoprotem and anticoagulation) that are similar to the
other third-generation products It has also been mtro-
duced recently
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"Diagnostic" and "referral" bias. A third objection is
that all studies might have overestimated the risk of
contraceptives because of a bias toward the diagnosis of
venous thrombosis in women who use oral contracep-
tives 14 If the association between oral contraceptives and
venous thrombosis would largely be a matter of diagnos-
tic bias, then we would expect that the association would
disappear, or be much dimimshed, among those cases in
which the diagnosis is so obvious that one does not need
the clue of oral contraceptive use to make the diagnosis
Inversely, the association would be strenger in cases m
which the diagnosis is uncertam, because the additional
Information on oral contraceptive use might have led to
the diagnosis This has never been shown true 15 1G In
two of the recent studies a separate analysis was made for
cases with defimte and probable diagnoses The m-
creased nsk of third- versus second-generation contra-
ceptives remamed at 2 6 and 2 8 for the WHO study and
at 2 2 and 2 2 for the UK-GPRD study ' l
The incidence problem. Another argument is that the
newer studies have shown only a lower frequency of
thrombosis among second-generation users, instead of a
higher one among third-generation users τ/ι Compari-
sons are made with older studies that showed higher
frequencies of thrombosis This disregards the diagnostic
problems of venous thrombosis The best compansons
remam those withm the same study, because the same
diagnostic cntena have been used, all studies are mter-
nally consistent in showmg the mcreased risk
Time trends. It was argued that an mcrease in the
Overall incidence of venous thromboembohsm has never
been demonstrated among young women, whereas such
an mcrease would have been expected if third-genera-
tion contraceptives really carned twice the risk I4 This
contradiction does not exist, because there has been an
mcrease in venous thrombosis-related mortality among
young women in the United Kingdom and m The
Netherlands 17 18 Moreover, it was found that among
younger women the risk of fatal venous thrombosis is
higher than the risk of death from myocardial mfarction
This Information, which was debated in subsequent
correspondence (see our acknowledgment at the end of
the article), is important äs a guide in prescribmg to
younger women
"Switching" bias. A new bias has been proposed, the
"switchmg bias," which would occur when women switch
from second- to third-generation products, for example,
because of "headaches and dizzmess " It is said that this
might mdicate an mcreased risk for venous thrombosis 14
The lack of a medical basis for this argument makes it
impossible to address it meanmgfully It has also been
argued that switchmg of brand of contraceptive pill was
in the past most often from second to third generation lq
No reason for switchmg that is associated with the risk of
venous thrombosis has been demonstrated
Biologie plausibility: New coagulation findings
It has been argued that there is no biologic plausi-
bility for an mcrease in venous thrombosis risk of
third- over second-generation contraceptives M How-
ever, the exact mechanism by which oral contracep
tives cause deep venous thrombosis was never under-
stood
Very recently, researchers20 from Maastricht, The
Netherlands, have shown that women who use third-
generation contraceptives acquire a degree of resistance
to the blood's own anticoagulation System, the protein
C/S System, that is close to the degree of activated
protein C resistance that is witnessed in persons who
carry the factor V Leiden mutation In contrast, women
usmg second-generation contraceptives show only about
half of this effect, a difference that was highly statistically
significant The "Leiden mutation" is a mutation in
coagulation factor V that renders it less sensitive to
mactivation by activated protein C 21 Persons who carry
this mutation have about an eightfold risk for venous
thrombosis, which is indeed similar to the overall risk of
third-generation contraceptives In earlier epidemiologic
studies it was found that carnership of the mutation
strongly mteracts with oral contraceptive use Women
who both carry the mutation and use oral contraceptives
have a nsk of thrombosis that is mcreased more than
thirtyfold il This mcrease m risk is of the order of
magnitude for the mcrease m homozygotes for the
mutation, whose risk mcrease is fiftyfold or more 2S
Interestmgly, m the new test System from Maastricht,
heterozygote carners of the mutation who use oral
contraceptives have coagulation results that are similar to
those of homozygotes, agam corroboratmg the epidemi-
ologic estimates
Comment
When we examme the arguments lhat studies showmg a
higher nsk of venous thrombosis for third-generation contra-
ceptives are biased, the arguments are found to have been
largely dismissed by the data From an epidemiologic pomt of
view this does not yet lead to complete certamty Unknown
biases that are therefore unmeasured and uncontrolled always
remam possible They remain a matter of behef Nevertheless,
the collective evidence that we have at present is difficult to
refute Therefore the most rational epidemiologic pomt of
view is that a greater nsk of deep venous thrombosis among
users of third-generation contraceptives is likely The epidemi-
ologic evidence has very recently been corroborated by new
coagulation findings These findings have importance beyond
the third- and second-generation controversy, because they
shed new light on the mechamsms of venous thrombosis with
oral contraceptive use and confirm earlier epidemiologic
findings of a synergy between oral contraceptive use and
carnership of the factor V Leiden mutation in the causaüon of
venous thrombosis
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Because the controversy on third-generation oral con-
traceptives and deep venous thrombosis has generated a
large volume of correspondence in several Journals, we
have cited only references that give an overview of several
Imes of argument or make specific poinls
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